The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Soliton Appoints Aesthetic Executive Veteran Brad Hauser as President and Chief Executive Officer

Article-Soliton Appoints Aesthetic Executive Veteran Brad Hauser as President and Chief Executive Officer

Soliton
Soliton, Inc., a medical device company with a novel and proprietary aesthetic platform technology, today announced the appointment of Brad A. Hauser as President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017 acquisition of ZELTIQ Aesthetics, Inc.

Soliton, Inc., a medical device company with a novel and proprietary aesthetic platform technology, today announced the appointment of Brad A. Hauser as President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017 acquisition of ZELTIQ Aesthetics, Inc.

"We are extremely excited to welcome Brad Hauser as CEO. We believe this is a monumental and pivotal appointment for the future of Soliton given Brad's well-established reputation in the aesthetics industry. Brad's deep expertise in aesthetics and his leadership in the commercialization of CoolSculpting serve as a powerful endorsement for the potential of the Soliton RAP device. As a long-standing member of our Board, Brad has provided excellent guidance and insight for the Soliton pipeline. We are very encouraged by the commercialization experience and skill set he brings to the CEO role," Walter Klemp, Soliton Co-Founder and Executive Chairman commented.

Mr. Hauser's extensive knowledge of the aesthetic market stems from his many years of valuable industry experience. Prior to Allergan's acquisition of ZELTIQ, Mr. Hauser held a number of positions for CoolSculpting including Senior Vice President of Research and Development and Vice President of Product and Clinical Strategy. Previously, Mr. Hauser held multiple leadership roles in the aesthetic industry, including Executive Vice President of Commercial Operations at Cutera, Director of Research and Development at Medicis, and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his Bachelor of Arts in Human Biology from Stanford University. He joined Soliton's Board of Directors in June 2018. 

"I am thrilled to be joining the Soliton team. We are at a very exciting point in the organization's life cycle and are gearing up to launch an innovative technology that has the potential to change how the industry addresses two real patient needs: faster, effective tattoo removal and a completely non-invasive solution for cellulite reduction, which is currently pending FDA clearance," said Mr. Hauser.

Read more here 

 

Source:

Soliton, Inc.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish